Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study

T. L. Bush, L. D. Cowan, E. Barrett-Connor, M. H. Criqui, J. M. Karon, R. B. Wallace, H. A. Tyroler and B. M. Rifkind

The association of exogenous estrogen use and hysterectomy status with all-cause mortality was examined in 2,269 white women, aged 40 to 69 years, who had been followed up for an average of 5.6 years in the Lipid Research Clinics Program Follow-up Study. A total of 72 deaths occurred during this period. The relative risk of death in estrogen users compared with nonusers was 0.54 in gynecologically intact women, 0.34 in hysterectomized women, and 0.12 in bilaterally oophorectomized women. The risk of death in estrogen users, irrespective of hysterectomy status, was 0.37 times that in nonusers (3.4/1,000 v 9.3/1,000). The significant negative association of estrogen use with mortality persisted after multivariate adjustment for confounding factors. Hysterectomy status alone was not a significant predictor of death. Some, but not all, of the lower risk of mortality in estrogen users can be accounted for by increased levels of high-density lipoprotein cholesterol.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats
Bhuiyan et al.
Am. J. Physiol. Endocrinol. Metab. 2007;293:E1606-E1614.
ABSTRACT | FULL TEXT  

Enhanced Risk Assessment in Asymptomatic Individuals With Exercise Testing and Framingham Risk Scores
Mora et al.
Circulation 2005;112:1566-1572.
ABSTRACT | FULL TEXT  

Long term effects of hysterectomy on mortality: nested cohort study
Iversen et al.
BMJ 2005;330:1482.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Cardiovascular Disease: What Went Wrong and Where Do We Go From Here?
Dubey et al.
Hypertension 2004;44:789-795.
ABSTRACT | FULL TEXT  

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence
Stampfer and Colditz
Int J Epidemiol 2004;33:445-453.
FULL TEXT  

An Epidemiologist Looks at Hormones and Heart Disease in Women
Barrett-Connor
J. Clin. Endocrinol. Metab. 2003;88:4031-4042.
FULL TEXT  

Female Hormones and Thrombosis
Rosendaal et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:201-210.
ABSTRACT | FULL TEXT  

Gender Differences in Vascular Smooth Muscle Reactivity to Increases in Extracellular Sodium Salt
Barron et al.
Hypertension 2002;39:425-432.
ABSTRACT | FULL TEXT  

Trudy L. Bush
Herrington et al.
Circulation 2001;104:1332-1332.
FULL TEXT  

In Memoriam: Trudy L. Bush (1949-2001)
Gold and Kelsey
Am J Epidemiol 2001;153:823-824.
FULL TEXT  

Gender-specific reduction in contractility and [Ca2+]i in vascular smooth muscle cells of female rat
Murphy and Khalil
Am. J. Physiol. Cell Physiol. 2000;278:C834-C844.
ABSTRACT | FULL TEXT  

Consumption of Soy Protein Reduces Cholesterol Absorption Compared to Casein Protein Alone or Supplemented with an Isoflavone Extract or Conjugated Equine Estrogen in Ovariectomized Cynomolgus Monkeys
Greaves et al.
J. Nutr. 2000;130:820-826.
ABSTRACT | FULL TEXT  

Antagonistic Effects of 17ß-Estradiol, Progesterone, and Testosterone on Ca2+ Entry Mechanisms of Coronary Vasoconstriction
Crews and Khalil
Arterioscler. Thromb. Vasc. Bio. 1999;19:1034-1040.
ABSTRACT | FULL TEXT  

Prediction of Coronary Heart Disease Using Risk Factor Categories
Wilson et al.
Circulation 1998;97:1837-1847.
ABSTRACT | FULL TEXT  

Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal Monkeys
Clarkson et al.
J. Clin. Endocrinol. Metab. 1998;83:721-726.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Therapy and Mortality
Grodstein et al.
NEJM 1997;336:1769-1776.
ABSTRACT | FULL TEXT  

Hormonal Treatment of Postmenopausal Women
Belchetz
NEJM 1994;330:1062-1071.
FULL TEXT